22/07/2022 (Agence Europe) – The European Medicines Agency (EMA) has announced that it is recommending an extension of the indication for Imvanex vaccine developed by Bavarian Nordic A/S to include protecting adults from the monkeypox disease. Ankara’s modified live vaccine had a marketing authorisation since 31 July 2013 for use in the prevention of smallpox. The EMA states that the recommendations of the Committee for Medicinal Products for Human Use are based on data from studies...